Results for this period
First quarter1 January 2026 to 31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
The real estate business reported higher revenue and profit, primarily due to increased tenant rental income at Cocoon City. The pharmaceutical business reported higher revenue and profit due to contributions from new drug sales and lower selling, general and administrative expenses. The machinery-related business reported lower revenue and profit due to the timing mismatch associated with the chassis model change and other factors. The textiles business reported higher profit as sales of heat-resistant fibers and other products remained solid.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026 to 31 March 2026 |
| Net Sales | ¥11,157 million (YoY -0.9%) |
| Operating profit | ¥2,040 million (YoY +20.3%) |
| Ordinary income | ¥2,309 million (YoY +19.4%) |
| Profit attributable to owners of the parent | ¥1,777 million (YoY +31.9%) |
| Net income per share | ¥56.16 |
| Equity ratio | End of the current fiscal period 64.9 / End of previous period 63.8 |
| Total assets | ¥154,849 million |
| Net assets | ¥102,618 million |
| Full-year earnings forecast | Net Sales ¥41,100 million (YoY +1.1%) / Operating profit ¥5,500 million (YoY -6.1%) / Ordinary income ¥6,900 million (YoY -4.4%) / Net income ¥5,200 million (YoY -9.8%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥60 → ¥60（0.0%） |
| Segment revenue | Real estate ¥2,944 million (YoY +7.2%), Pharmaceuticals ¥2,626 million (YoY +3.3%), Machinery-related ¥3,382 million (YoY -9.3%), Fibers ¥1,615 million (YoY +0.2%), Other ¥588 million (YoY -5.7%) |
| Segment profit | Real estate ¥1,231 million (YoY +16.5%), Pharmaceuticals ¥125 million (YoY +458.5%), Machinery-related ¥618 million (YoY -7.1%), Fibers ¥275 million (YoY +58.2%), Other ¥-14 million |
| Depreciation and amortization | ¥720 million |
| Breakdown of extraordinary income (loss) | No extraordinary income for the period (—); no extraordinary loss disclosed |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | No (no newly consolidated or excluded companies, or company names, disclosed) |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No (no eligible attendees) |
| Issued Shares at Period-End | 35,215,000 Shares |
| Treasury Shares at Period-End | 3,565,462 Shares |
| Factors Behind Changes in Business Performance | The real estate business reported higher revenue and profit, primarily due to increased tenant rental income at Cocoon City. The pharmaceutical business reported higher revenue and profit due to contributions from new drug sales and lower selling, general and administrative expenses. The machinery-related business reported lower revenue and profit due to the timing mismatch associated with the chassis model change and other factors. The textiles business reported higher profit as sales of heat-resistant fibers and other products remained solid. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue decreased as lower revenue from the machinery-related business more than offset higher revenue from the real estate business. Operating profit increased, primarily due to higher profit from the real estate business. Factors cited for the pharmaceutical business included contributions from new drug sales and lower selling, general and administrative expenses, while the machinery-related business was affected by a timing mismatch between production and sales associated with the chassis model change.